This Small-Cap Stock Announced a Deal With Eli Lilly. Then Its Shares Doubled

Ginkgo Bioworks shares have doubled since its Eli Lilly AI drug-discovery partnership was announced on Sept. 15, putting its market capitalization at about $1 billion, but the article cautions that the rally may be ahead of its fundamentals. In the quarter ended June 30, revenue fell to $20.2 million from $39.1 million a year earlier, while its operating loss widened slightly to $58.5 million from $58.2 million. The article recommends a wait-and-see approach, noting Ginkgo remains unprofitable and its stock is down 97% over five years.

Analysis

The key asymmetry is that this deal may be strategically useful to Lilly without becoming financially material to Lilly—or meaningfully monetizable for Ginkgo. Lilly can treat external data as an option alongside its own AI efforts; that limits Ginkgo’s bargaining power unless the collaboration produces repeatable, exclusive, or paid use. The value test for Ginkgo is conversion into recurring revenue and improving unit economics, not the announcement or the size of its data library.

Near term, the sharp sentiment rebound leaves DNA exposed to a reversal if investors treat partnership activity as evidence of operating recovery. The risk is amplified by the gap between commercial excitement and reported results, but a short can be vulnerable to further deal headlines and squeeze dynamics. Over 1–3 months, watch for specific disclosed economics, customer expansion, and revenue trends. Over 6–18 months, the structural question is whether Ginkgo can monetize its platform at scale while funding operations; verify cash runway, dilution, and segment-level revenue before sizing exposure. Lilly’s downside from this particular partnership appears more limited absent evidence that it changes R&D productivity or spending.

Contrarian angle: the market may be overpricing the announcement as a near-term revenue inflection, but the rebound alone does not establish that DNA is overvalued; a measurable contract or broader customer conversion could sustain optimism. Falsify the cautious thesis with sustained revenue growth, improving operating losses, and disclosed recurring economics. A failure to show those alongside continued cash consumption would strengthen it.

Key Decisions for Investors

• Do not buy DNA solely on partnership headlines. Put it on an event watchlist and require evidence of paid, recurring contribution in subsequent disclosures before reconsidering.
• For a bearish expression, consider a small, defined-risk DNA put spread only if option pricing, liquidity, and implied volatility make the premium acceptable; avoid an uncapped short given headline and squeeze risk. Reassess after the next results or any contract-economics disclosure.
• Treat LLY as a separate fundamental exposure, not a hedge for DNA: this collaboration alone is insufficient evidence to revise Lilly earnings expectations. Revisit only if Lilly links the tool to measurable R&D productivity, pipeline decisions, or spending changes.
• Track Ginkgo’s cash runway, share-count changes, revenue by business line, and operating-loss trajectory. Continued dilution or weak commercial conversion despite new partnerships would invalidate a durable-recovery case; sustained growth with improving losses would challenge the bearish setup.